

type of report	Current report
number	72/2013
company	PHARMENA

September 2013 monthly report

The Management Board of Pharmena S.A. hereby presents its monthly report for September 2013.

1. Information on trends and events occurring in the Issuer's market environment

To the best knowledge of the Management Board, in September 2013 no trends or events occurred in the Issuer's market environment which could significantly influence financial results of the company.

In September 2013, Pharmena accomplished sales revenue from its dermatological cosmetics in the amount 1,972,000 PLN, which constitutes a decrease by 84% when compared to the revenue achieved in an analogical period of the previous year. Higher sales in September 2013 was a result of promotional and sales campaigns of all Dermena products, especially concerning the Dermena Complex dietary supplement.

In the said period, Pharmena S.A. enhanced the availability of its products and carried out marketing actions in order to increase sales profit from marketed products.

In the area of works over 1-MNA dietary supplement, during the period covered by this report, the following events occurred:

The Management Board of PHARMENA S.A. informed that on 18th September 2013, the Company received notification that Food Standards Agency (FSA) in London formally accepted the application for authorisation of 1-MNA as new food ingredient by regulation no. 258/97, on 31st August 2013.

Also, the Company informed that the application for authorisation of 1-MNA was accessed during the meeting of the Advisory Committee on Novel Foods and Processes (ACNFP) on 26th June 2013. The ACNFP Committee, which together with Food Standards Agency (FSA) performs the assessments of applications for authorisation of new food ingredients, requested the Company to submit additional information on the application. The Company forwarded additional clarification to the ACNFP Committee. Further assessment of application for authorisation of 1-MNA as new food ingredient will be held by circulation.

The Food Standards Agency conducts 21-day public consultation, as part of the assessment of applications. Also, the application for authorisation of 1-MNA as new food ingredient will undergo such consultation, which will be held simultaneously with substantive evaluation.

The assessment of application for authorisation of 1-MNA will be prepared by Food Standards Agency until 30th November 2013. Successful authorisation will open EU markets for the dietary supplement.

The 1-MNA dietary supplement will be an innovative product with capacity to influence the risk biomarkers of cardiovascular diseases and to stimulate the endogenous (natural) production of prostacyclin. Low levels of prostacyclin in human organism increase the risk of atherosclerosis. Studies have shown that the concentration of endogenous 1-MNA in human organism decreases with age. 1-MNA dietary supplement can complement 1-MNA deficiency in the organism and therefore stimulate the production of prostacyclin which reduces the risk of atherosclerosis development.

Pursuant to resolution no. 452/2007 of 3rd July 2007 r. with further amendments, adopted by the Management Board of Warsaw Stock Exchange S.A. in Warsaw (GPW), after the session on 20th September 2013, the Stock Exchange performed a quarterly revision concerning the NCIndex30 portfolio. The NCIndex30 index portfolio covers 30 the most liquid companies introduced to trading on the NewConnect market. According to the methodology of the index, the PHARMENA S.A. shares entered the NCIndex30 portfolio after the session on 20th September 2013.

According to an announcement of the Management Board of Warsaw Stock Exchange dated 26th September 2013, the company PHARMENA S.A. was qualified to the NC Lead segment. Yet another nomination to this prestigious segment of companies resulted from high free float of PHARMENA S.A. shares, as well as the company's dutiful fulfilment of informational requirements and corporate governance rules.

Moreover in September 2013, Issuer's Capital Group continued its research and development work on new products and searched for new applications for active substances protected by patents and patent applications owned by the Issuer's Capital Group.

2. Achievement of the goals of an issue

In September 2013, Pharmena S.A. did not make any money expenditure directly on issue-related purposes. However, a subsidiary company Cortria Corporation spent its funds on preparing tablets for clinical trials, patent fees, and consultancy services in the field of application documentation for phase II clinical trials.

3. A list of all information published by the Issuer in the form of current reports in the reporting period from 1st September 2013 to 30th September 2013.

During the period covered by this report, Pharmena S.A. published the following reports in EBI system:

- Current report no. 62/2013 of 13-09-2013 – August 2013 monthly report
- Current report no. 63/2013 of 16-09-2013 – Qualification of PHARMENA S.A. to NCIndex30
- Current report no. 64/2013 of 19-09-2013 – Acceptance of application for authorisation of 1-MNA as new food ingredient
- Current report no. 65/2013 of 27-09-2013 – Qualification of PHARMENA S.A. to NC Lead segment

During the period covered by this report, Pharmena S.A. did not publish any reports in ESPI system.

4. Investor's calendar for October 2013
Until 14th November 2013 – publication of October 2013 monthly report.

Legal basis: Resolution No. 795/2008 of the Warsaw Stock Exchange Management Board dated 31st November 2008 concerning the adoption of the codes of best practice applicable on the NewConnect market, Appendix 1, point 16.

Representatives of the company:

- Konrad Palka – President of the Board
- Marzena Wieczorkowska – Vice President of the Board